With the Allergan acquisition, we are bringing together over 30 brands and leadership positions to expand and diversify our product portfolio. This allows us to have immediate scale and profitability to advance our innovative science pipeline that brings patients ground-breaking medicines across a wide spectrum of therapeutic need/critical therapeutic areas.
We continue to build a sustainable company for the long term that provides profitable growth for shareholders, financial flexibility to invest and expand our reach to help address the needs of people and communities around the world.
